Skip to content

Retrospective Survey of Hyperkalemia in Hemodialysis

A Multicenter Retrospective Survey of Hyperkalemia Clinical Burden on Hemodialysis Facility-level in China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05020717
Acronym
Visualize-HD
Enrollment
300
Registered
2021-08-25
Start date
2021-09-30
Completion date
2022-12-31
Last updated
2021-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis Complication

Brief summary

This study aim to describe hyperkalemia clinical burden and investigate the risk factors associated with the burden on HD facility level.

Detailed description

This study is an observational survey study. We estimate 300 hemodialysis (HD) centres will be enrolled in the study. Summarized data on serum potassium (sK) after long interdialytic interval (LIDI), facility practice pattern and patient characteristics which may be related with sK management, and death records information including number of deaths for each centre will be collected. All the data collected and analysed are on HD facility level, not on patient-level. We are aiming to describe hyperkalemia clinical burden and investigate the risk factors associated with the burden on HD facility level. Association between sK management and long-term outcome will also be explored.

Interventions

None listed

Sponsors

AstraZeneca
CollaboratorINDUSTRY
Peking University People's Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

\- For HD centers: * ≥ 100 patients under MHD within 3 years prior the study initiation * Willing to participate in the study * Have routine blood collection after LIDI * Have death records For HD patients: • On chronic HD for ≥ 3 months

Exclusion criteria

* Blood test on other days than those after LIDI * Unable to provide detailed data required by study protocol * Being unable to comply with study-specified procedure

Design outcomes

Primary

MeasureTime frameDescription
To investigate the risk factors associated with hyperkalemia clinical burden on HD facility level3 yearsExamine the association of risk factors at current status to hyperkalemia prevalence on HD facility level

Secondary

MeasureTime frameDescription
To describe hyperkalemia clinical burden on HD facility level3 yearsConstitution ratio of different sK levels after LIDI in ranges: (0, 3.5\], (3.5, 5.0\], (5.0, 5.5\], (5.5, 6.0\], (6.0, 6.5\], (6.5, 7.0\], (7.0\ ) mmol/L in HD centers
To describe sK management pattern on HD facility level3 yearsProportion of patients on 3 times/week, 5 times/2 weeks, 2 times/week, less than 2 times/week, and other frequencies of HD treatment Proportion of patients with dialysate potassium concentration at 2.0 mmol/L, 2.5 mmol/L, 3.0 mmol/L and others Proportion of patients with sK testing on monthly, once per 3 months, once per \> 3 months and others
To investigate the risk factors associated with crude mortality on HD facility level3 yearsExamine the association of risk factors back to 3 years ago to crude mortality on HD facility level, risk factors back to 3 years ago including: Constitution ratio of different sK levels after LIDI in ranges: (0, 3.5\], (3.5, 5.0\], (5.0, 5.5\], (5.5, 6.0\], (6.0, 6.5\], (6.5, 7.0\], (7.0\ ) mmol/L in HD centers back to 3 years ago. Constitution ratio of last sK levels before death in ranges: (0, 3.5\], (3.5, 5.0\], (5.0, 5.5\], (5.5, 6.0\], (6.0, 6.5\], (6.5, 7.0\], (7.0\ ) mmol/L in HD centers Key sK management factors (dialysis frequency, dialysate potassium concentration, sK testing frequency) Other factors (length of dialysis/session, patients dialysis vintage, residual renal function, etiology of ESRD, comorbidities, medication use)

Other

MeasureTime frameDescription
To investigate the risk factors associated with sK > 6.0 mmol/L and sK > 6.5 mmol/L on HD facility level3 yearsExamine the association of the facility-level risk factors at current status with sK ≥ 6.0 mmol/L and ≥ 6.5 mmol/L

Countries

China

Contacts

Primary ContactLi Zuo
zuoli@bjmu.edu.cn+86(10)88324008
Backup ContactXinju Zhao
zxjrmyy@163.com+86(10)88325018

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026